NCT00690833

Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Wake Forest University · Academic / Other
• Sex: All
• Age: 3 Months
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to better understand how this study drug works when people use it to treat atopic dermatitis. Desonate has been approved by the US Food and Drug Administration (FDA) for atopic dermatitis.

Detailed description

To assess the efficacy of a desonide hydrogel 0.05% in both young children (age \<13) and older subjects (ages 13 and up) with mild to moderate atopic dermatitis

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	topical desonide hydrogel 0.05%	apply the smallest amount of study medication possible that is just sufficient to cover all lesions of the standard cortisone-type medication twice daily (morning and evening) for up to 4 weeks to all of their AD lesions

Timeline

• Start date: 2007-08-01
• Primary completion: 2007-12-01
• Completion: 2009-11-01
• First posted: 2008-06-05
• Last updated: 2018-09-10
• Results posted: 2017-03-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study